Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Eisai Ties Up with Quintiles to Develop Anticancer Drug Candidates
November 9, 2009
- Pharm. Business Will Continue to Growth: Mr Ludwig of BD
November 9, 2009
- REGULATORY NEWS IN BRIEF
November 9, 2009
- Half-Year Business Results of Major Domestic Companies
November 9, 2009
- 3 Societies Call For Vaccination of Girls Aged 11-14 with Cervarix
November 9, 2009
- Astellas Licenses MDV3100 for Prostate Cancer from Medivation
November 9, 2009
- PMDA Needs 2,000-3,000 Staff Members for Simultaneous Approval with US, EU: Chief Executive Kondo
November 9, 2009
- Japan Is the Most Important Market in Asia: Mr Barr of Covance
November 9, 2009
- Korosho Considers Extension of Tax Break on Research Expenses
November 9, 2009
- Takeda to Develop Global Business as “Medium-Sized Global Pharma”: Mr Hasegawa
November 9, 2009
- Japan Is Obliged to Promote Use of Generics: Dr Suzuki
November 9, 2009
- Medipal Aims at Sales of ¥30 Bil. in China in FY2012
November 9, 2009
- Dr Adachi Confirms ConservativeStance toward Industry Proposal
November 9, 2009
- Generic Amlodipine Comparable to Original Version: NPO Report
November 9, 2009
- Chuikyo Back to Work
November 9, 2009
- Daiichi Sankyo Applies for Injectable Levofloxacin on the Same Day as IP High Court Ruling
November 9, 2009
- Nissui to Launch OTC Version of Epadel in Spring 2010
November 9, 2009
- Cravit's Patent Extension Rejected by IP High Court
November 9, 2009
- Hatoyama Administration to Change Medical Expenditure Curtailment Policy
November 2, 2009
- Kyowa Kirin Transfers Neu-Up to Yakult
November 2, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…